PROLYNX, LLC
Business process automation and data integration software platform
New patent ·
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Founded
- 2019
- Latest Form D
- $55K, Sep 2020
- Total capital
- $1.3M
- Federal grants
- $1.3M
- 4 awards · 2014–2020
- Rank in peer group#233 of 326
- Private capital raised
- $55K
- 1 Form D · last Sep 2020
- 74 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 15
- 25 pending · first 2016
- Rank in peer group#14 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$55K
- Federal grantHealth and Human S · Phase I · A long acting parathyroid hormone (PTH) 1-34 for treatment of hypoparathyroidism$246K
- Federal grantHealth and Human S · Phase I · A facile approach for preparing dual agonists with long lifetimes and balanced activities$150K
- Federal grantHealth and Human S · Phase I · A facile approach for preparing dual-agonists with long lifetimes and balanced activities$150K
- Federal grantNSF · Phase II · SBIR Phase II: Controlled Drug Release from and Degradation of Hydrogels$743K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
70months
from PROLYNX, LLC’s first federal award to its first private round.
- First federal award · Nov 2014
- NSF · $743K
- First Form D · Sep 2020
- $55K · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#14 · top 4%
- Linked publications#5 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anurag BagariaDirectorNamed in SEC Form D filings
- Daniel SantiExecutive Officer, DirectorNamed in SEC Form D filings
- Marc EdwardsDirectorNamed in SEC Form D filings
- Michael RabsonDirectorNamed in SEC Form D filings
- Scott J. KarchmerExecutive OfficerNamed in SEC Form D filings
- William J. RutterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- New patentSteam Sterilization Of Hydrogels Crosslinked By Beta-eliminative LinkersUSPTOUS 12,758,661
- GrantedSlow-release Cytokine ConjugatesUSPTOUS 12,697,395
- PendingMethods Of Treating Cancer With Long-acting Topoisomerase I InhibitorUSPTOApplication 19101243
Show all 40 patent records
- Steam Sterilization Of Hydrogels Crosslinked By Beta-eliminative LinkersOct 13, 2026 · US 12,758,661Granted
- Slow-release Cytokine ConjugatesAug 4, 2026 · US 12,697,395Granted
- Methods Of Treating Cancer With Long-acting Topoisomerase I InhibitorFeb 12, 2026 · Application 19101243Pending
- Treating Cancer With Long-acting Topoisomerase I InhibitorFeb 5, 2026 · Application 19101241Pending
- Conjugation LinkersJan 8, 2026 · Application 19213933Pending
- Hydrogels With Biodegradable CrosslinkingNov 25, 2025 · US 12,478,680Granted
- Conjugated Inhibitors Of Dna Damage ResponseNov 18, 2025 · US 12,472,261Granted
- Protocol For Minimizing Toxicity Of Combination Dosages And Imaging Agent For VerificationOct 9, 2025 · Application 19088784Pending
- Improved Conjugation LinkersJul 22, 2025 · US 12,364,771Granted
- High-throughput Microemulsification MembraneJun 6, 2024 · Application 18282976Pending
- Synergistic Cancer TreatmentMar 14, 2024 · Application 18220742Pending
- Extended Release Hydrogel Conjugates Of C-natriuretic PeptidesFeb 8, 2024 · Application 18038687Pending
- Protocol For Minimizing Toxicity Of Combination Dosages And Imaging Agent For VerificationOct 12, 2023 · Application 18118650Pending
- Synergistic Cancer TreatmentAug 22, 2023 · US 11,730,836Granted
- Hydrogels With Biodegradable CrosslinkingSep 27, 2022 · US 11,454,861Granted
- Steam Sterilization Of Hydrogels Crosslinked By Beta-eliminative LinkersAug 25, 2022 · Application 17631325Pending
- Hydrogels With Biodegradable CrosslinkingNov 23, 2021 · US 11,179,470Granted
- Hydrogels With Biodegradable CrosslinkingNov 23, 2021 · US 11,181,803Granted
- Protocol For Minimizing Toxicity Of Combination Dosages And Imaging Agent For VerificationNov 19, 2020 · Application 16961633Pending
- Extended Release Conjugates Of Exenatide AnalogsMay 28, 2020 · Application 16085139Pending
- Conjugates Of Somatostatin AnaloguesSep 17, 2019 · US 10,413,594Granted
- Hydrogels With Biodegradable CrosslinkingSep 3, 2019 · US 10,398,779Granted
- Slow-release Conjugates Of SN-38Jul 9, 2019 · US 10,342,792Granted
- Conjugates Of Somatostatin AnaloguesOct 2, 2018 · US 10,086,049Granted
- Slow-release Conjugates Of SN-38Jul 10, 2018 · US 10,016,411Granted
- Prodrugs And Drug-macromolecule Conjugates Having Controlled Drug Release RatesJul 12, 2016 · US 9,387,254Granted
- Sealants Having Controlled DegrationDec 10, 2015 · Application 14762424Pending
- Peg Conjugates Of ExenatideSep 11, 2014 · Application 14352644Pending
- Extended Release Hydrogel Conjugates Of C-natriuretic PeptidesApplication PCTUS2021060763Pending
- Treating Cancer With Long-acting Topoisomerase I InhibitorApplication PCTUS2023071592Pending
- Conjugation LinkersApplication 62830280Pending
- Slow-release Cytokine ConjugatesApplication 62839112Pending
- Locoregional Therapies Using Slow-release ConjugatesApplication 63552588Pending
- High-throughput Microemulsification MembraneApplication PCTUS2022020959Pending
- Pegylated IL-15 Receptor Alpha CytokinesApplication 63632231Pending
- Locoregional Therapies Using Slow-release ConjugatesApplication PCTUS2025015638Pending
- Treating Cancer With Long-acting Topoisomerase I InhibitorApplication 63370476Pending
- Methods Of Treating Cancer With Long-acting Topoisomerase I InhibitorApplication 63370478Pending
- Extended-release Conjugates Of Lipidated Peptides, And Uses ThereofApplication 63673637Pending
- Prostate-specific Membrane Antigen Targeted Deep-tumor Penetration Of Polymer Nanodrugs And Methods Of Use ThereofApplication 63402375Pending
Recent research by its founders
- PEG-RLI: A Long-Acting IL-15 Agonist That Produces Massive Levels of CD8+ and CD44hiCD8+ Cells for Cancer Immunotherapy20260 cites
- Supplementary Figure S10 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer20260 cites
- Supplementary Figure S11 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer20260 cites
Related companies, and why
- ABSCO THERAPEUTICS, INC. D/B/A ABSCOTXSimilar federal contract value in Biotech · null in contracts
- Stipple BioSimilar federal contract value in Biotech · null in contracts
- Nostopharma, LLCSimilar federal contract value in Biotech · null in contracts
- SQZ Biotechnologies CompanySimilar federal contract value in Biotech · null in contracts
- KSQ TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Kite Pharma, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .